☆ 4.5 Article

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib

MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK

Lirong Liu et al.

Summary: A rare EML4-ALK (E6;A18) fusion variant was found in a patient with lung adenocarcinoma, which showed a positive response to alectinib. This evidence suggests that alectinib may be effective for this rare fusion type of non-small cell lung cancer, highlighting the importance of drug selection for patients with this subtype. Further studies are needed to understand the function of this variant.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Review Oncology

The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis

Shasha Wang et al.

Summary: The study found that patients with EML4-ALK fusion variant 1 showed no significant difference in prognosis compared to non-v1 patients, while patients with variant 3 had worse survival outcomes and shorter overall survival compared to non-v3 patients.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Oncology

Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance

Di Liu et al.

Summary: After treatment with the first-line therapy drug alectinib for ALK-positive non-small-cell lung cancer, a patient rapidly acquired drug resistance, followed by multi-drug resistance and a short survival time.

LUNG CANCER (2021)

Add to Collection

Article Oncology

Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines

David S. Ettinger et al.

Summary: The NCCN Guidelines for NSCLC cover all aspects of management, with recent updates focusing on targeted therapies, immunotherapies, and their respective biomarkers.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC

Weihua Li et al.

Summary: Variable genomic breakpoints of ALK, ROS1, and RET fusions in NSCLC can affect the efficacy of matched targeted therapy. Uncommon fusions may not reliably predict therapy response, and functional validation by RNA or protein assay can improve accurate detection and interpretation of rare fusions.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma A case report

Aixia Sui et al.

Summary: This case presents a patient with ALK-rearranged lung adenocarcinoma who developed acquired resistance to ALK inhibition, with the BRAF V600E mutation identified as a novel resistance mechanism.

MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers

Peiyi Xia et al.

Summary: This study identified complex ALK rearrangements in NSCLC, with 14 cases classified into three types. All cases expressed canonical EML4-ALK fusion transcripts confirmed by RNA-based NGS. Patients with complex ALK rearrangements treated with ALK inhibitors showed no difference in progression-free survival compared to those with canonical ALK fusions.

JOURNAL OF TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Oncology

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK plus ) NSCLC

Shannon S. Zhang et al.

Summary: This study discusses the impact of EML4-ALK variants on NSCLC and response to ALK TKIs. EML4-ALK 1 and 3 are the most common variants, dominant in ALK+ NSCLC. Short (v3 and v5) and long (v1, v2, v5', v7, and v8) EML4-ALK variants show differential response to TKIs.

LUNG CANCER (2021)

Add to Collection

Article Oncology

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer

Ruoshi Shi et al.

LUNG CANCER (2020)

Add to Collection

Article Multidisciplinary Sciences

Diagnosis of fusion genes using targeted RNA sequencing

Erin E. Heyer et al.

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Oncology

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

Ryma Benayed et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Respiratory System

Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients

Lin Nong et al.

JOURNAL OF THORACIC DISEASE (2019)

Add to Collection

Article Oncology

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations

Lauretta Odogwu et al.

ONCOLOGIST (2018)

Add to Collection

Article Oncology

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

David Planchard et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer

Solange Peters et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations

Doraid Alrifai et al.

LUNG CANCER (2013)

Add to Collection

Article Oncology

A Novel EML4-ALK Variant Exon 6 of EML4 Fused to Exon 19 of ALK

Roland Penzel et al.

JOURNAL OF THORACIC ONCOLOGY (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.